BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 35321560)

  • 21. Immune checkpoint inhibitor-related myasthenia gravis, myositis and myocarditis: a triad but not at the same time?
    Cooksley T; Weaver J; McNamara M; Lorigan P
    QJM; 2024 Jun; 117(5):373-374. PubMed ID: 38229249
    [No Abstract]   [Full Text] [Related]  

  • 22. Immune checkpoint inhibitors induced side effects of the peripheral nervous system.
    Hundsberger T; Schreiner B; Roth P
    Curr Opin Neurol; 2023 Oct; 36(5):427-431. PubMed ID: 37639489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pembrolizumab-Induced Fatal Myasthenia, Myocarditis, and Myositis in a Patient with Metastatic Melanoma: Autopsy, Histological, and Immunohistochemical Findings-A Case Report and Literature Review.
    Giovannini E; Bonasoni MP; D'Aleo M; Tamagnini I; Tudini M; Fais P; Pelotti S
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune Checkpoint Inhibitor-Associated Myositis: A Distinct Form of Inflammatory Myopathy.
    Saygin D; Ghosh N; Reid P
    J Clin Rheumatol; 2022 Oct; 28(7):367-373. PubMed ID: 35696731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis.
    Wang C; Zeng H; Fang W; Song L
    Invest New Drugs; 2023 Apr; 41(2):333-339. PubMed ID: 36988830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myocarditis and myositis/myasthenia gravis overlap syndrome induced by immune checkpoint inhibitor followed by esophageal hiatal hernia: A case report and review of the literature.
    Yin B; Xiao J; Wang X; Li X; Guan Y; Chen J; Han P; Li K; Wang J
    Front Med (Lausanne); 2022; 9():950801. PubMed ID: 36457566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune Checkpoint Inhibitor-induced Myositis.
    Jayan A; Mammen AL; Suarez-Almazor ME
    Rheum Dis Clin North Am; 2024 May; 50(2):281-290. PubMed ID: 38670726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis.
    Hamada N; Maeda A; Takase-Minegishi K; Kirino Y; Sugiyama Y; Namkoong H; Horita N; Yoshimi R; Nakajima H;
    Front Immunol; 2021; 12():803410. PubMed ID: 34938300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management.
    Farina A; Villagrán-García M; Honnorat J
    Rev Neurol (Paris); 2023 Jun; 179(5):506-515. PubMed ID: 36934022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical spectrum of neuromuscular complications after immune checkpoint inhibition.
    Puwanant A; Isfort M; Lacomis D; Živković SA
    Neuromuscul Disord; 2019 Feb; 29(2):127-133. PubMed ID: 30638612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nivolumab-induced Myositis and Myocarditis with Positive Anti-titin Antibody and Anti-voltage-gated Potassium Channel Kv1.4 Antibody.
    Ono R; Iwai Y; Yamazaki T; Takahashi H; Hori Y; Fukushima K; Saotome T
    Intern Med; 2022 Oct; 61(19):2973-2979. PubMed ID: 35314545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Consider Myocarditis When Patients Treated with Immune Checkpoint Inhibitors Present with Ocular Symptoms.
    Rhee JY; Torun N; Neilan TG; Guidon AC
    Oncologist; 2022 May; 27(5):e402-e405. PubMed ID: 35348772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune checkpoint inhibitor-associated myositis and myasthenia gravis overlap: Understanding the diversity in a case series.
    Wong EYT; Yong MH; Yong KP; Tan EH; Toh CK; Kanesvaran R; Takano A; Ng QS
    Asia Pac J Clin Oncol; 2021 Oct; 17(5):e262-e267. PubMed ID: 32985078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myasthenia Gravis Induced by Immune Checkpoint Inhibitors: An Emerging Neurotoxicity in Neuro-Oncology Practice: Case Series.
    Marco C; Simó M; Alemany M; Casasnovas C; Domínguez R; Vilariño N; Calvo M; Martín-Liberal J; Brenes J; Sabater-Riera J; Bruna J; Velasco R
    J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36614930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune Checkpoint Inhibitor-Induced Myocarditis With Concurrent Myasthenia Gravis.
    Kuniyoshi J; Huang R; Choi H; Bernas M; Techasatian W; Nishimura Y
    Can J Cardiol; 2023 Nov; 39(11):1646-1648. PubMed ID: 37330137
    [No Abstract]   [Full Text] [Related]  

  • 36. Immune Checkpoint Inhibitor-Induced Myositis/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit.
    Deharo F; Carvelli J; Cautela J; Garcia M; Sarles C; Maues de Paula A; Bourenne J; Gainnier M; Bichon A
    J Clin Med; 2022 Sep; 11(19):. PubMed ID: 36233479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians.
    Raschi E; Rossi S; De Giglio A; Fusaroli M; Burgazzi F; Rinaldi R; Potena L
    Drug Saf; 2023 Sep; 46(9):819-833. PubMed ID: 37341925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune Checkpoint Inhibition-Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade.
    Nelke C; Pawlitzki M; Kerkhoff R; Schroeter CB; Aktas O; Neuen-Jacob E; Polzin A; Meuth SG; Ruck T
    Neurol Neuroimmunol Neuroinflamm; 2024 Jan; 11(1):. PubMed ID: 37884388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: A case report and literature review.
    Gao L; Li X; Guo Z; Tang L; Peng J; Liu B
    Medicine (Baltimore); 2022 Dec; 101(49):e32240. PubMed ID: 36626474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurological adverse events related to immune-checkpoint inhibitors in Spain: a retrospective cohort study.
    Fonseca E; Cabrera-Maqueda JM; Ruiz-García R; Naranjo L; Diaz-Pedroche C; Velasco R; Macias-Gómez A; Milisenda JC; Muñoz-Farjas E; Pascual-Goñi E; Gállego Perez-Larraya J; Saiz A; Dalmau J; Blanco Y; Graus F; Martinez-Hernandez E;
    Lancet Neurol; 2023 Dec; 22(12):1150-1159. PubMed ID: 37977714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.